Literature DB >> 1824744

Response to treatment with an analog of the luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis.

G A Rossi1, B Balbi, S Oddera, S Lantero, C Ravazzoni.   

Abstract

Pulmonary lymphangioleiomyomatosis is a chronic devastating disorder afflicting women of childbearing age, characterized by proliferation of atypical smooth muscle in the lung. Attempts to treat this disease have shown that a number of hormonal manipulations may be helpful but that surgical oophorectomy alone or associated with administration of progesterone is the most effective treatment. This report describes the response to treatment with an analog of luteinizing-hormone-releasing hormone, goserelin, which is able to induce a marked suppression of the secretion of ovarian sex steroid and demonstrates with pulmonary function studies, arterial blood gas determinations, and bronchoalveolar lavage parameters that this patient's disease was responsive to this agent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824744     DOI: 10.1164/ajrccm/143.1.174

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.

Authors:  S Johnson
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 2.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

Review 3.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

4.  Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Authors:  Connie G Glasgow; Wendy K Steagall; Angelo Taveira-Dasilva; Gustavo Pacheco-Rodriguez; Xiong Cai; Souheil El-Chemaly; Marsha Moses; Thomas Darling; Joel Moss
Journal:  Respir Med       Date:  2010-07       Impact factor: 3.415

5.  Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.

Authors:  Sergio Harari; Roberto Cassandro; Iacopo Chiodini; Jacopo Chiodini; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Chest       Date:  2007-12-10       Impact factor: 9.410

Review 6.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

7.  Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study.

Authors:  I Wahedna; S Cooper; J Williams; I C Paterson; J R Britton; A E Tattersfield
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

8.  A case of lymphangioleiomyomatosis originated in the pelvic cavity.

Authors:  Jung-Mi Han; Kyung-Hee Lee; Sung-Joo Kim; Chae-Chun Rhim; Young-Han Park; Jung-Bae Kang; Sun-Young Jeon
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

9.  Hormonal manipulation with letrozole in the treatment of metastatic malignant pecoma.

Authors:  P Le; A Garg; G Brandao; A Abu-Sanad; L Panasci
Journal:  Curr Oncol       Date:  2014-06       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.